MIGRAINE TREATMENT BEYOND TRADITIONAL THERAPIES: CURRENT TRENDS AND FUTURE DIRECTIONS

Dominik Fidorowicz; Rafał Siedlecki; Katarzyna Bednarczuk; Marta Góral; Aleksandra Irena Skuza; Emilia Torbacka; Agnieszka Mikłaszewicz; Katarzyna Helena Sergiel; Daniel Sagan; Magda  Downar-Zapolska

doi:10.31435/ijitss.2(50).2026.5991

Authors

Dominik Fidorowicz Independent Public Provincial Integrated Hospital in Szczecin – Arkońska, Szczecin, Poland https://orcid.org/0009-0005-2184-4004
Rafał Siedlecki Independent Public Provincial Integrated Hospital in Szczecin – Zdunowo, Szczecin, Poland https://orcid.org/0009-0005-2653-2368
Katarzyna Bednarczuk Independent Public Provincial Integrated Hospital in Szczecin – Arkońska, Szczecin, Poland https://orcid.org/0009-0000-5207-6718
Marta Góral Independent Public Provincial Integrated Hospital in Szczecin – Zdunowo, Szczecin, Poland https://orcid.org/0009-0004-1063-897X
Aleksandra Irena Skuza Independent Public Provincial Integrated Hospital in Szczecin – Arkońska, Szczecin, Poland https://orcid.org/0009-0000-3071-2015
Emilia Torbacka Pomeranian Medical University Hospital No. 2, Szczecin, Poland https://orcid.org/0009-0001-4624-3564
Agnieszka Mikłaszewicz Pomeranian Medical University Hospital No. 1, Szczecin, Poland https://orcid.org/0009-0007-7423-6103
Katarzyna Helena Sergiel Independent Public Provincial Integrated Hospital in Szczecin – Arkońska, Szczecin, Poland https://orcid.org/0009-0002-6627-9852
Daniel Sagan Independent Public Provincial Integrated Hospital in Szczecin – Arkońska, Szczecin, Poland https://orcid.org/0009-0007-8247-9842
Magda Downar-Zapolska Independent Public Provincial Integrated Hospital in Szczecin – Arkońska, Szczecin, Poland https://orcid.org/0009-0008-4646-0404

DOI:

https://doi.org/10.31435/ijitss.2(50).2026.5991

Keywords:

Migraine Treatment, CGRP-Targeted Therapies, CGRP Monoclonal Antibodies, Gepants, Lasmiditan, Neuromodulation and Nerve Blocks, PACAP-Targeted Therapies

Abstract

Migraine is a highly prevalent neurological disease associated with considerable personal, social, and economic burden. The disease represents a major contributor to disability and reduced quality of life. Over the years migraine pharmacotherapy has evolved from non-specific vasoconstrictive agents such as ergot alkaloids to mechanism-based therapies targeting serotonin and CGRP pathways, including triptans, gepants, ditans, and monoclonal antibodies. This review analyzes modern treatment approaches on migraine and evaluates their clinical relevance.

References

Puledda, F., Silva, E. M., Suwanlaong, K., et al. (2023). Migraine: From pathophysiology to treatment. Journal of Neurology, 270, 3654–3666. https://doi.org/10.1007/s00415-023-11706-1

Quartetti, U., Brighina, F., Gambino, G., Frinchi, M., Bellafiore, M., Tabacchi, G., Vasto, S., Accardi, G., Amato, A., Giardina, M., Mazzucco, W., Boffetta, P., Giglia, G., & Di Liberto, V. (2025). Forecasting migraine attacks by managing daily lifestyle: A systematic review as a basis to develop predictive algorithms. PAIN Reports, 10(2), Article e1247. https://doi.org/10.1097/PR9.0000000000001247

Tuttolomondo, A., & Simonetta, I. (2023). Molecular research on migraine: From pathogenesis to treatment. International Journal of Molecular Sciences, 24(10), Article 8681. https://doi.org/10.3390/ijms24108681

Kuburas, A., & Russo, A. F. (2023). Shared and independent roles of CGRP and PACAP in migraine pathophysiology. The Journal of Headache and Pain, 24, Article 34. https://doi.org/10.1186/s10194-023-01569-2

Burch, R., & Rittenberg, E. (2025). New treatments for migraine: CGRP monoclonal antibodies, gepants, and ditans. BMJ, 390, Article e085564. https://doi.org/10.1136/bmj-2025-085564

Sharma, J., Soni, R., & Singh, S. (2025). Recent trends in the pharmacological treatment of chronic migraine: A systematic review of randomized controlled trials. Cureus, 17, Article e95602. https://doi.org/10.7759/cureus.95602

Chiang, C.-C., & Schwedt, T. J. (2020). Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine—The monoclonal antibodies and gepants. Progress in Brain Research, 255, 143–170. https://doi.org/10.1016/bs.pbr.2020.06.019

Capi, M., De Angelis, V., De Bernardini, D., De Luca, O., Cipolla, F., Lionetto, L., Simmaco, M., & Martelletti, P. (2021). CGRP receptor antagonists and 5-HT1F receptor agonist in the treatment of migraine. Journal of Clinical Medicine, 10(7), Article 1429. https://doi.org/10.3390/jcm10071429

Caronna, E., Alpuente, A., Torres-Ferrus, M., & Pozo-Rosich, P. (2024). CGRP monoclonal antibodies and CGRP receptor antagonists (gepants) in migraine prevention. In Handbook of clinical neurology (Vol. 199, pp. 107–124). Elsevier. https://doi.org/10.1016/B978-0-12-823357-3.00024-0

Sevivas, H., & Fresco, P. (2022). Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: A systematic review. European Journal of Medical Research, 27, Article 86. https://doi.org/10.1186/s40001-022-00716-w

Sacco, S., Amin, F. M., Ashina, M., et al. (2022). European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene-related peptide pathway for migraine prevention—2022 update. The Journal of Headache and Pain, 23, Article 67. https://doi.org/10.1186/s10194-022-01431-x

Rivera-Mancilla, E., Villalón, C. M., & MaassenVanDenBrink, A. (2020). CGRP inhibitors for migraine prophylaxis: A safety review. Expert Opinion on Drug Safety, 19(10), 1237–1250. https://doi.org/10.1080/14740338.2020.1811229

Nicol, K. S., & Burkett, J. G. (2025). An update on CGRP monoclonal antibodies for the preventive treatment of episodic migraine. Current Pain and Headache Reports, 29, Article 55. https://doi.org/10.1007/s11916-025-01365-4

Wang, X., Chen, Y., Song, J., & You, C. (2021). Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: A systematic review and network meta-analysis. Frontiers in Pharmacology, 12, Article 649143. https://doi.org/10.3389/fphar.2021.649143

Hong, P., Tan, T., Liu, Y., & Xiao, J. (2020). Gepants for abortive treatment of migraine: A network meta-analysis. Brain and Behavior, 10(8), Article e01701. https://doi.org/10.1002/brb3.1701

Jakubowska, B., & Sowa-Kućma, M. (2025). Gepants: Targeting the CGRP pathway for migraine relief. Frontiers in Pharmacology, 16, Article 1708226. https://doi.org/10.3389/fphar.2025.1708226

Moreno-Ajona, D., Villar-Martínez, M. D., & Goadsby, P. J. (2022). New generation gepants: Migraine acute and preventive medications. Journal of Clinical Medicine, 11(6), Article 1656. https://doi.org/10.3390/jcm11061656

Moriarty, M. A., & Barch, C. A. (2025). Gepants in primary care: A targeted approach to acute and preventive treatment of migraine. Pain and Therapy, 14, 1263–1278. https://doi.org/10.1007/s40122-025-00757-z

Li, D., Abreu, J., & Tepper, S. J. (2023). A brief review of gepants. Current Pain and Headache Reports, 27(9), 479–488. https://doi.org/10.1007/s11916-023-01142-1

Alsaadi, T. M., Adel, F., Alsaffarini, K. W. B., El Jadam, C., Alkhateri, A., Pagdato, B., & Suliman, R. (2025). Bridging CGRP mAbs with gepants: An innovative approach to address the wearing-off phenomenon. Clinical Neurology and Neurosurgery, 258, Article 109183. https://doi.org/10.1016/j.clineuro.2025.109183

Ferrari, A., & Rustichelli, C. (2021). Rational use of lasmiditan for acute migraine treatment in adults: A narrative review. Clinical Therapeutics, 43(4), 654–670. https://doi.org/10.1016/j.clinthera.2021.01.020

Mecklenburg, J., Raffaelli, B., Neeb, L., Sánchez del Río, M., & Reuter, U. (2020). The potential of lasmiditan in migraine. Therapeutic Advances in Neurological Disorders, 13, Article 1756286420967847. https://doi.org/10.1177/1756286420967847

Sabet, H., Abbas, A., Abouelmagd, M. E., et al. (2025). Ultrasound-guided greater occipital nerve block for chronic migraine: A systematic review and meta-analysis. Head & Face Medicine, 21, Article 81. https://doi.org/10.1186/s13005-025-00554-1

Atraszkiewicz, D., Ünal, E., Bassett, P., Morell-Ducos, F., & Bahra, A. (2025). Greater occipital nerve block for the treatment of migraine: An umbrella review, systematic review, and meta-analysis. Cephalalgia, 45(12). https://doi.org/10.1177/03331024251398390

Diener, H. C. (2025). PACAP and migraine. Brain, 148(8), 2646–2649. https://doi.org/10.1093/brain/awaf131

Alabbad, S., Figueredo, N., Yuan, H., & Silberstein, S. D. (2024). Developments in targeting calcitonin gene-related peptide. Expert Review of Neurotherapeutics, 24(5), 477–485. https://doi.org/10.1080/14737175.2024.2332754

Oliveira, R., Gil-Gouveia, R., & Puledda, F. (2024). CGRP-targeted medication in chronic migraine: Systematic review. The Journal of Headache and Pain, 25, Article 51. https://doi.org/10.1186/s10194-024-01753-y

Özge, A., Baykan, B., Bıçakçı, Ş., Ertaş, M., Atalar, A. Ç., Gümrü, S., & Karlı, N. (2024). Revolutionizing migraine management: Advances and challenges in CGRP-targeted therapies and their clinical implications. Frontiers in Neurology, 15, Article 1402569. https://doi.org/10.3389/fneur.2024.1402569

Pellesi, L., Garcia-Azorin, D., Rubio-Beltrán, E., Ha, W.-S., Messina, R., Ornello, R., Petrusic, I., Raffaelli, B., et al. (2024). Combining treatments for migraine prophylaxis: The state-of-the-art. The Journal of Headache and Pain, 25, Article 214. https://doi.org/10.1186/s10194-024-01925-w

Pozo-Rosich, P., Alpuente, A., Silberstein, S. D., Burstein, R., et al. (2024). Insights from 25 years of onabotulinumtoxinA in migraine: Mechanisms and management. Nature Reviews Neurology, 20(10), 555–568. https://doi.org/10.1038/s41582-024-01002-5